1. Diagnosis Related Group Costs in a Regulated Environment

   • Claude Le Pen
   • Gilles Berdeaux

   Current Opinion 22 September 2012 Pages: 115 - 120

2. New Generation Aromatase Inhibitors in Breast Cancer

   • Gerald M. Higa

   Leading Article 22 September 2012 Pages: 121 - 132

   

3. Pharmacoeconomic Considerations in Treating Ovarian Cancer

   • Diane Bodurka-Bevers
   • Charlotte C. Sun
   • David M. Gershenson

   Review Article 22 September 2012 Pages: 133 - 150

   

4. Valuing Health-Related Quality of Life

   • Colin Green
   • John Brazier
   • Mark Deverill

   Review Article 22 September 2012 Pages: 151 - 165

   

5. The Costs of Pharmacological Treatment for Major Depression

   • Rosanna Tarricone
   • Giovanni Fattore
   • Mauro Percudani

   Original Research Article 22 September 2012 Pages: 167 - 174

   

6. Pharmacoeconomics and Clinical Practice Guidelines

   • Anders Anell
   • Patrick Svarvar

   Original Research Article 22 September 2012 Pages: 175 - 185

   

7. Impact of Zanamivir Treatment on Productivity, Health Status and Healthcare Resource Use in Patients with Influenza

   • Fred Y. Aoki
   • Douglas M. Fleming
   • Sally Edmundson

   Original Research Article 22 September 2012 Pages: 187 - 195

   

8. Cost-of-Illness of Epilepsy in Italy

   • Patrizia Berto
   • P. Tinuper
   • S. Viaggi

   Original Research Article 22 September 2012 Pages: 197 - 208

   

9. Economic Analysis of Long Term Reversible Contraceptives

   • Ceri J. Phillips

   Original Research Article 22 September 2012 Pages: 209 - 221